鞠立霞 副主任医师，副教授
硕士招生类型：学术型
硕士招生专业：中医学
博士招生类型：学术型
博士招生专业：临床医学（中医学方向）
所在院系：附属肺科医院
联系方式：jvlixia@126.com
课题组链接：
研究方向
主要任职
科研业绩

肺癌的综合治疗Comprehensive treatment of lung cancer
医学博士，美国加州大学洛杉矶分校和加拿大麦吉尔大学访问****；兼任中国民族医药学会肺病分会理事；上海市中西医结合学会呼吸分会常务委员；上海市传统医学工程协会肿瘤专业委员会常务委员；Lung Cancer, Oncology Letter等多本SCI杂志审稿人。
MD,PhD. Visiting scholar of University of California at Los Angeles and McGill University in Canada funded by CSC. Member of council in pulmonary disease branch of China Medical Association of Minorities; Member of the standing committee in respiration branch of Shanghai Chinese Association of Integrative Medicine; Member of the standing committee in oncology branch of Shanghai Association of Traditional Medical Engineering; Reviewer of Lung Cancer, Oncology Letter and other SCI Journals.
出版专著一本，发表论文20余篇，包括SCI多篇，多篇文章被国际知名肿瘤大会如美国肿瘤大会（ASCO）、欧洲肿瘤年会（ESMO）、世界胸科大会（WCC）等收录并做大会演讲交流。主持包括国家自然科学基金等科研课题7项。
More than 20 articles and a monograph have been published，including some indexed by SCI.Some articles were published by famous international Cancer Congresses, such as ASCO, ESMO, WCC. 7 projects were carried out, including the projects from National Natural Science Foundation of China.
some of articles:1: Ju, L; Dong, Z; Yang, J; et al.Mechanism of intrinsic resistance of lung squamous cell carcinoma to epithelial growth factor receptor-tyrosine kinase inhibitors revealed by high-throughput RNA interference screening.[J].Oncol Lett.2020,20(6):363
2：Ju L, Han M, Su J, Wu C, Dong Z. A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib. Cancer Chemother Pharmacol. 2018 Sep;82(3):561-564.
3：Ju L, Han M, Li X, Zhao C. MicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion. J Cancer. 2017 May 11;8(7):1311-1318.
4: Ju L, Han M. Isolated brain metastasis as a late recurrence of completely resected non-small cell lung cancer. Oncol Lett. 2016 Jul;12(1):731-733.
5: Ju L, Han M, Zhao C, Li X. EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient. Lung Cancer. 2016 May;95:94-7.
6: Ju L, Zhou C. Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer. Cancer Biomark. 2013;13(5):329-36.
7: Ju L, Zhou C. Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer. Cancer Cell Int. 2013 Feb 13;13(1):15.
8: Ju L, Zhou C, Li W, Yan L. Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem. 2010 Dec 15;111(6):1565-74.
9：分阶段中药辅助靶向治疗EGFR敏感突变的非小细胞肺癌的临床研究、上海中医药大学学报（CN 31-1788/R）、2017,(03):18-22、第一兼通讯作者
10：分子靶向药物引起的肺癌患者肝毒性的中医证治体会、河北中医（CN 13-1067/R）、2017,(04):607-610、第一兼通讯作者
11：培元固本中药序贯化疗对晚期非小细胞肺癌免疫功能的影响、辽宁中医杂志（ CN 21-1128/R ）、2016,(11):2310-2312、第一作者
12：肺癌的精准治疗，专著，上海浦江教育出版社，2017.5